

PET and PET/CT in Cervical Cancer

Ahmed, R. S., Kim, R. Y., Duan, J., Meleth, S., De Los Santos, J. F. and Fiveash, J. B.: 2004, 'IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.' *Int J Radiat Oncol Biol Phys* **60**, 505-12.

Belhocine, T.: 2003, 'An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal.' *Int J Gynecol Cancer* **13**, 228-33.

Belhocine, T., Thille, A., Fridman, V., Albert, A., Seidel, L., Nickers, P., Kridelka, F. and Rigo, P.: 2002, 'Contribution of whole-body 18FDG PET imaging in the management of cervical cancer.' *Gynecol Oncol* **87**, 90-7.

Cham, D., Henderson, R. and Conti, P. S.: 2004, 'Virchow's Node on F-18 FDG PET/CT.' *Clin Nucl Med* **29**, 770-2.

Chander, S., Meltzer, C. C. and McCook, B. M.: 2002, 'Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography.' *Clin Nucl Med* **27**, 22-4.

Chang, T. C., Law, K. S., Hong, J. H., Lai, C. H., Ng, K. K., Hsueh, S., See, L. C., Chang, Y. C., Tsai, C. S., Chou, H. H., Huang, K. G., Liou, J. D., Lin, C. T., Chao, A., Chen, M. Y., Wu, T. I., Ma, S. Y. and Yen, T. C.: 2004, 'Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study.' *Cancer* **101**, 164-71.

Chang, W. C., Hung, Y. C., Lin, C. C., Shen, Y. Y. and Kao, C. H.: 2004, 'Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptotically elevated tumor marker serum levels--a preliminary report.' *Cancer Invest* **22**, 180-4.

Dehdashti, F., Grigsby, P. W., Mintun, M. A., Lewis, J. S., Siegel, B. A. and Welch, M. J.: 2003, 'Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.' *Int J Radiat Oncol Biol Phys* **55**, 1233-8.

Dose, J., Bohuslavizki, K., Huneke, B., Lindner, C. and Janicke, F.: 2000, 'Detection of Intramural Choriocarcinoma of the Uterus with 18F-FDG-PET. A Case Report.' *Clin Positron Imaging* **3**, 37-40.

Esthappan, J., Mutic, S., Malyapa, R. S., Grigsby, P. W., Zoberi, I., Dehdashti, F., Miller, T. R., Bosch, W. R. and Low, D. A.: 2004, 'Treatment planning guidelines

regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes.' *Int J Radiat Oncol Biol Phys* **58**, 1289-97.

Grigsby, P. W., Dehdashti, F. and Siegel, B. A.: 1999, 'FDG-PET Evaluation of Carcinoma of the Cervix.' *Clin Positron Imaging* **2**, 105-109.

Grigsby, P. W., Siegel, B. A. and Dehdashti, F.: 2001, 'Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.' *J Clin Oncol* **19**, 3745-9.

Grigsby, P. W., Siegel, B. A., Dehdashti, F. and Mutch, D. G.: 2003, 'Posttherapy surveillance monitoring of cervical cancer by FDG-PET.' *Int J Radiat Oncol Biol Phys* **55**, 907-13.

Grigsby, P. W., Siegel, B. A., Dehdashti, F., Rader, J. and Zoberi, I.: 2004, 'Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.' *J Clin Oncol* **22**, 2167-71.

Havrilesky, L. J., Wong, T. Z., Secord, A. A., Berchuck, A., Clarke-Pearson, D. L. and Jones, E. L.: 2003, 'The role of PET scanning in the detection of recurrent cervical cancer.' *Gynecol Oncol* **90**, 186-90.

Huh, S. J., Kang, M. K. and Han, Y.: 2004, 'Small bowel displacement system-assisted intensity-modulated radiotherapy for cervical cancer.' *Gynecol Oncol* **93**, 400-6.

Huh, S. J., Park, W. and Han, Y.: 2004, 'Interfractional variation in position of the uterus during radical radiotherapy for cervical cancer.' *Radiother Oncol* **71**, 73-9.
Kao, C. H.: 2003, 'FDG uptake in a huge uterine myoma.' *Clin Nucl Med* **28**, 249.

Kavanagh, B. D., Schefter, T. E., Wu, Q., Tong, S., Newman, F., Arnfield, M., Benedict, S. H., McCourt, S. and Mohan, R.: 2002, 'Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer.' *Semin Radiat Oncol* **12**, 260-71.

Koyama, K., Okamura, T., Kawabe, J., Ozawa, N., Torii, K., Umesaki, N., Miyama, M., Ochi, H. and Yamada, R.: 2003, 'Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.' *J Nucl Med* **44**, 353-8.

Lai, C. H., Huang, K. G., See, L. C., Yen, T. C., Tsai, C. S., Chang, T. C., Chou, H. H., Ng, K. K., Hsueh, S. and Hong, J. H.: 2004, 'Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.' *Cancer* **100**, 544-52.

- Lentz, S. S.: 2002, 'Endometrial carcinoma diagnosed by positron emission tomography: a case report.' *Gynecol Oncol* **86**, 223-4.
- Lerman, H., Metser, U., Grisaru, D., Fishman, A., Lievshitz, G. and Even-Sapir, E.: 2004, 'Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.' *J Nucl Med* **45**, 266-71.
- Lin, W. C., Hung, Y. C., Yeh, L. S., Kao, C. H., Yen, R. F. and Shen, Y. Y.: 2003, 'Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings.' *Gynecol Oncol* **89**, 73-6.
- Low, D. A., Grigsby, P. W., Dempsey, J. F., Mutic, S., Williamson, J. F., Markman, J., Chao, K. S., Klein, E. E. and Purdy, J. A.: 2002, 'Applicator-guided intensity-modulated radiation therapy.' *Int J Radiat Oncol Biol Phys* **52**, 1400-6.
- Ma, S. Y., See, L. C., Lai, C. H., Chou, H. H., Tsai, C. S., Ng, K. K., Hsueh, S., Lin, W. J., Chen, J. T. and Yen, T. C.: 2003, 'Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients.' *J Nucl Med* **44**, 1775-83.
- Malyapa, R. S., Mutic, S., Low, D. A., Zoberi, I., Bosch, W. R., Laforest, R., Miller, T. R. and Grigsby, P. W.: 2002, 'Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer.' *Int J Radiat Oncol Biol Phys* **54**, 1140-6.
- Miller, T. R., Pinkus, E., Dehdashti, F. and Grigsby, P. W.: 2003, 'Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.' *J Nucl Med* **44**, 192-7.
- Mutic, S., Grigsby, P. W., Low, D. A., Dempsey, J. F., Harms, W. B., Laforest, R., Bosch, W. R. and Miller, T. R.: 2002, 'PET-guided three-dimensional treatment planning of intracavitary gynecologic implants.' *Int J Radiat Oncol Biol Phys* **52**, 1104-10.
- Mutic, S., Malyapa, R. S., Grigsby, P. W., Dehdashti, F., Miller, T. R., Zoberi, I., Bosch, W. R., Esthappan, J. and Low, D. A.: 2003, 'PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study.' *Int J Radiat Oncol Biol Phys* **55**, 28-35.
- Nakahara, T., Fujii, H., Ide, M., Mochizuki, Y., Takahashi, W., Yasuda, S., Shohtsu, A. and Kubo, A.: 2001, 'F-18 FDG uptake in endometrial cancer.' *Clin Nucl Med* **26**, 82-3.
- Nakamoto, Y., Eisbruch, A., Achtyes, E. D., Sugawara, Y., Reynolds, K. R., Johnston, C. M. and Wahl, R. L.: 2002, 'Prognostic value of positron emission

tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.' *Gynecol Oncol* **84**, 289-95.

Narayan, K., McKenzie, A. F., Hicks, R. J., Fisher, R., Bernshaw, D. and Bau, S.: 2003, 'Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy.' *Int J Gynecol Cancer* **13**, 657-63.

Portelance, L., Chao, K. S., Grigsby, P. W., Bennet, H. and Low, D.: 2001, 'Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation.' *Int J Radiat Oncol Biol Phys* **51**, 261-6.

Reinhardt, M. J., Ehrlich-Braun, C., Vogelgesang, D., Ihling, C., Hoyerle, S., Mix, M., Moser, E. and Krause, T. M.: 2001, 'Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.' *Radiology* **218**, 776-82.

Reinhardt, M. J., Matthies, A. and Biersack, H. J.: 2002, 'PET-imaging in tumors of the reproductive tract.' *Q J Nucl Med* **46**, 105-12.

Roeske, J. C., Lujan, A., Rotmensch, J., Waggoner, S. E., Yamada, D. and Mundt, A. J.: 2000, 'Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.' *Int J Radiat Oncol Biol Phys* **48**, 1613-21.

Rose, P. G., Adler, L. P., Rodriguez, M., Faulhaber, P. F., Abdul-Karim, F. W. and Miraldi, F.: 1999, 'Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study.' *J Clin Oncol* **17**, 41-5.

Ryu, S. Y., Kim, M. H., Choi, S. C., Choi, C. W. and Lee, K. H.: 2003, 'Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.' *J Nucl Med* **44**, 347-52.

Shimotsu, Y., Ishida, Y., Fukuchi, K., Hayashida, K., Toba, M., Hamada, S., Takamiya, M., Satoh, T., Nakanishi, N. and Nishimura, T.: 1998, 'Fluorine-18-fluorodeoxyglucose PET identification of cardiac metastasis arising from uterine cervical carcinoma.' *J Nucl Med* **39**, 2084-7.

Singh, A. K., Grigsby, P. W., Dehdashti, F., Herzog, T. J. and Siegel, B. A.: 2003, 'FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma.' *Int J Radiat Oncol Biol Phys* **56**, 489-93.

Soper, J. T.: 2001, 'Radiographic imaging in gynecologic oncology.' *Clin Obstet Gynecol* **44**, 485-94.

Sugawara, Y., Eisbruch, A., Kosuda, S., Recker, B. E., Kison, P. V. and Wahl, R. L.: 1999, 'Evaluation of FDG PET in patients with cervical cancer.' *J Nucl Med* **40**, 1125-31.

Sun, S. S., Chen, T. C., Yen, R. F., Shen, Y. Y., Changlai, S. P. and Kao, A.: 2001, 'Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.' *Anticancer Res* **21**, 2957-61.

Torizuka, T., Kanno, T., Futatsubashi, M., Okada, H., Yoshikawa, E., Nakamura, F., Takekuma, M., Maeda, M. and Ouchi, Y.: 2003, 'Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.' *J Nucl Med* **44**, 1051-6.

Tran, B. N., Grigsby, P. W., Dehdashti, F., Herzog, T. J. and Siegel, B. A.: 2003, 'Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.' *Gynecol Oncol* **90**, 572-6.

Tsai, C. S., Chang, T. C., Lai, C. H., Tsai, C. C., Ng, K. K., Hsueh, S., Yen, T. C. and Hong, J. H.: 2004, 'Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.' *Int J Radiat Oncol Biol Phys* **58**, 1506-12.

Umesaki, N., Tanaka, T., Miyama, M., Kawabe, J., Okamura, T., Koyama, K., Ochi, H. and Ogita, S.: 2000, 'The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.' *Oncol Rep* **7**, 1261-4.

Umesaki, N., Tanaka, T., Miyama, M., Tokuyama, O., Kawamura, N., Ogita, S., Kawabe, J., Okamura, T., Koyama, K. and Ochi, H.: 2000, 'Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography.' *Oncol Rep* **7**, 53-6.

Unger, J. B., Ivy, J. J., Connor, P., Charrier, A., Ramaswamy, M. R., Ampil, F. L. and Monsour, R. P.: 2004, 'Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.' *Gynecol Oncol* **94**, 212-6.

Vesselle, H. J. and Miraldi, F. D.: 1998, 'FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls.' *Radiographics* **18**, 805-23; discussion 823-4.

Wong, T. Z., Jones, E. L. and Coleman, R. E.: 2004, 'Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.' *Mol Imaging Biol* **6**, 55-62.

Yeh, L. S., Hung, Y. C., Shen, Y. Y., Kao, C. H., Lin, C. C. and Lee, C. C.: 2002, 'Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings.' *Oncol Rep* **9**, 1289-92.

Yen, T. C., Ng, K. K., Ma, S. Y., Chou, H. H., Tsai, C. S., Hsueh, S., Chang, T. C., Hong, J. H., See, L. C., Lin, W. J., Chen, J. T., Huang, K. G., Lui, K. W. and Lai, C. H.: 2003, 'Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.' *J Clin Oncol* **21**, 3651-8.

Yen, T. C., See, L. C., Lai, C. H., Yah-Huei, C. W., Ng, K. K., Ma, S. Y., Lin, W. J., Chen, J. T., Chen, W. J., Lai, C. R. and Hsueh, S.: 2004, '18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.' *J Nucl Med* **45**, 22-9.

Zhuang, H., Yamamoto, A. J., Sinha, P., Pourdehnad, M., Liu, Y. and Alavi, A.: 2001, 'Similar pelvic abnormalities on FDG positron emission tomography of different origins.' *Clin Nucl Med* **26**, 515-7.

PET and PET/CT in Ovarian Cancer

2004, '[2003 update of recommendations for clinical practice: standards, options and recommendations for the use of FDG-PET in the management of gynaecological and breast cancers].' *Gynecol Obstet Fertil* **32**, 352-71.

Alibazoglu, H., Megremis, D., Ali, A. and LaMonica, G.: 1998, 'Injection artifact on FDG PET imaging.' *Clin Nucl Med* **23**, 264-5.

Baum, R. P. and Przetak, C.: 2001, 'Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET).' *Q J Nucl Med* **45**, 257-68.

Bohdiewicz, P. J., Juni, J. E., Ball, D. and Dworkin, H.: 1995, 'Krukenberg tumor and lung metastases from colon carcinoma diagnosed with F-18 FDG PET.' *Clin Nucl Med* **20**, 419-20.

Bohdiewicz, P. J., Scott, G. C., Juni, J. E., Fink-Bennett, D., Wilner, F., Nagle, C. and Dworkin, H. J.: 1995, 'Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.' *Clin Nucl Med* **20**, 230-6.

Chang, W. C., Hung, Y. C., Kao, C. H., Yen, R. F., Shen, Y. Y. and Lin, C. C.: 2002, 'Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on

asymptomatically elevated serum levels of tumor marker.' *Neoplasma* **49**, 329-33.

Cho, S. M., Ha, H. K., Byun, J. Y., Lee, J. M., Kim, C. J. and Nam-Koong, S. E.: 2002, 'Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.' *AJR Am J Roentgenol* **179**, 391-5.

Clavo, A. C., Brown, R. S. and Wahl, R. L.: 1995, 'Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.' *J Nucl Med* **36**, 1625-32.

Clavo, A. C. and Wahl, R. L.: 1996, 'Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells.' *J Nucl Med* **37**, 502-6.

Coleman, R. E.: 1998, 'Clinical PET in Oncology.' *Clin Positron Imaging* **1**, 15-30.
De Potter, T., Flamen, P., Van Cutsem, E., Penninckx, F., Filez, L., Bormans, G., Maes, A. and Mortelmans, L.: 2002, 'Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.' *Eur J Nucl Med Mol Imaging* **29**, 525-9.

Ding, X. L., Shen, K., Lang, J. H., Wu, M., Huang, H. F., Pan, L. Y. and Yang, J. X.: 2003, '[Role of positron emission tomography in diagnosis of recurrent ovarian cancer].' *Zhonghua Fu Chan Ke Za Zhi* **38**, 667-9.

Drieskens, O., Stroobants, S., Gysen, M., Vandenbosch, G., Mortelmans, L. and Vergote, I.: 2003, 'Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer.' *Gynecol Obstet Invest* **55**, 130-4.

Fenchel, S., Grab, D., Nuessle, K., Kotzerke, J., Rieber, A., Kreienberg, R., Brambs, H. J. and Reske, S. N.: 2002, 'Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings.' *Radiology* **223**, 780-8.

Fenchel, S., Kotzerke, J., Stohr, I., Grab, D., Nussle, K., Rieber, A., Kreienberg, R., Brambs, H. J. and Reske, S. N.: 1999, '[Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose].' *Nuklearmedizin* **38**, 101-7.

Garcia Velloso, M. J., Boan Garcia, J. F., Villar Luque, L. M., Aramendia Beitia, J. M., Lopez Garcia, G. and Richter Echeverria, J. A.: 2003, '[F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].' *Rev Esp Med Nucl* **22**, 217-23.

Higashi, K., Clavo, A. C. and Wahl, R. L.: 1993, 'Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.' *J Nucl Med* **34**, 414-9.

- Higashi, K., Clavo, A. C. and Wahl, R. L.: 1993, 'In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.' *J Nucl Med* **34**, 773-9.
- Hoh, C. K., Hawkins, R. A., Glaspy, J. A., Dahlbom, M., Tse, N. Y., Hoffman, E. J., Schiepers, C., Choi, Y., Rege, S. and Nitzsche, E.: 1993, 'Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.' *J Comput Assist Tomogr* **17**, 582-9.
- Hoh, C. K., Schiepers, C., Seltzer, M. A., Gambhir, S. S., Silverman, D. H., Czernin, J., Maddahi, J. and Phelps, M. E.: 1997, 'PET in oncology: will it replace the other modalities?' *Semin Nucl Med* **27**, 94-106.
- Hubner, K. F., McDonald, T. W., Niethammer, J. G., Smith, G. T., Gould, H. R. and Buonocore, E.: 1993, 'Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG).' *Gynecol Oncol* **51**, 197-204.
- Hubner, K. F., McDonald, T. W., Smith, G. T. and Thie, J. A.: 1999, 'Detection of Recurrent Ovarian Cancer by PET Using FDG.' *Clin Positron Imaging* **2**, 346.
- Huglo, D. and Vinatier, D.: 2004, '[Utilization of PET scan in breast and gynaecologic cancers].' *Gynecol Obstet Fertil* **32**, 330-9.
- Jimenez Bonilla, J., Moya Garcia, F., Zomeno Rodriguez, M., Ordovas Oromendia, A., Konsvintseva, O., Martin Jorge, R. and Maldonado Suarez, A.: 2001, '[Detection of relapse in ovarian cancer by PET-FDG].' *Rev Esp Med Nucl* **20**, 128-9.
- Juweid, M., Sharkey, R. M., Alavi, A., Swayne, L. C., Herskovic, T., Hanley, D., Rubin, A. D., Pereira, M. and Goldenberg, D. M.: 1997, 'Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.' *J Nucl Med* **38**, 257-60.
- Karlan, B. Y., Hawkins, R., Hoh, C., Lee, M., Tse, N., Cane, P. and Glaspy, J.: 1993, 'Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.' *Gynecol Oncol* **51**, 175-81.
- Karlan, B. Y., Hoh, C., Tse, N., Futoran, R., Hawkins, R. and Glaspy, J.: 1993, 'Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube.' *Gynecol Oncol* **49**, 383-8.
- Kawahara, K., Yoshida, Y., Kurokawa, T., Suzuki, Y., Nagahara, K., Tsuchida, T., Okazawa, H., Fujibayashi, Y., Yonekura, Y. and Kotsuji, F.: 2004, 'Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to

magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography.' *J Comput Assist Tomogr* **28**, 505-16.

Kim, S., Chung, J. K., Kang, S. B., Kim, M. H., Jeong, J. M., Lee, D. S. and Lee, M. C.: 2004, '[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.' *Eur J Nucl Med Mol Imaging* **31**, 196-201.

Koyama, K., Okamura, T., Kawabe, J., Ozawa, N., Torii, K., Umesaki, N., Miyama, M., Ochi, H. and Yamada, R.: 2003, 'Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.' *J Nucl Med* **44**, 353-8.

Kubik-Huch, R. A., Dorffler, W., von Schulthess, G. K., Marincek, B., Kochli, O. R., Seifert, B., Haller, U. and Steinert, H. C.: 2000, 'Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.' *Eur Radiol* **10**, 761-7.

Kurokawa, T., Yoshida, Y., Kawahara, K., Tsuchida, T., Fujibayashi, Y., Yonekura, Y. and Kotsuji, F.: 2002, 'Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.' *Ann Nucl Med* **16**, 491-3.

Kurokawa, T., Yoshida, Y., Kawahara, K., Tsuchida, T., Okazawa, H., Fujibayashi, Y., Yonekura, Y. and Kotsuji, F.: 2004, 'Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.' *Int J Cancer* **109**, 926-32.

Leitha, T., Cesnik, R., Steiner, E. and Fruhwald, F.: 2004, 'Use of FDG-PET in the differential diagnosis of a single bone lesion in ovarian cancer.' *Clin Nucl Med* **29**, 204-5.

Lerman, H., Metser, U., Grisaru, D., Fishman, A., Lievshitz, G. and Even-Sapir, E.: 2004, 'Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.' *J Nucl Med* **45**, 266-71.
Linke, R., Schroeder, M., Helmberger, T. and Voltz, R.: 2004, 'Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.' *Neurology* **63**, 282-6.

Liu, R. S.: 2000, '31. Clinical Application of.' *Clin Positron Imaging* **3**, 185.
Maldonado, A., Sancho, F., Perez-Carrion, R., Senor, C., Moya, F., Trampal, C., Ossola, G., Ortega, F. and Melgarejo, M.: 1999, 'Value of FDG-PET in the Therapeutic Management of Recurrent Ovarian Cancer. Experience in 31 Patients.' *Clin Positron Imaging* **2**, 321.

Menzel, C., Dobert, N., Hamscho, N., Zaplatnikov, K., Vasvatekis, S., Matic, V., Wordehoff, N. and Grunwald, F.: 2004, 'The Influence of CA 125 and CEA Levels on the Results of (18)F-Deoxyglucose Positron Emission Tomography in Suspected Recurrence of Epithelial Ovarian Cancer.' *Strahlenther Onkol* **180**, 497-501.

Nakamoto, Y., Saga, T., Ishimori, T., Mamede, M., Togashi, K., Higuchi, T., Mandai, M., Fujii, S., Sakahara, H. and Konishi, J.: 2001, 'Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.' *AJR Am J Roentgenol* **176**, 1449-54.

Pecking, A. P., Mechelany-Corone, C. and Pichon, M. F.: 2000, '[1959-1999: from serum markers to 18-FDG in oncology. The experience of the Rene-Huguenin Center].' *Pathol Biol (Paris)* **48**, 819-24.

Picchio, M., Sironi, S., Messa, C., Mangili, G., Landoni, C., Gianolli, L., Zangheri, B., Viganò, R., Aletti Gde, M., De Cobelli, F., Del Maschio, A., Ferrari, A. and Fazio, F.: 2003, 'Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.' *Q J Nucl Med* **47**, 77-84.

Reinhardt, M. J., Matthies, A. and Biersack, H. J.: 2002, 'PET-imaging in tumors of the reproductive trac.' *Q J Nucl Med* **46**, 105-12.

Romer, W., Avril, N., Dose, J., Ziegler, S., Kuhn, W., Herz, M., Janicke, F. and Schwaiger, M.: 1997, '[Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose].' *Rofo* **166**, 62-8.

Rose, P. G., Faulhaber, P., Miraldi, F. and Abdul-Karim, F. W.: 2001, 'Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.' *Gynecol Oncol* **82**, 17-21.

Schroder, W., Zimny, M., Rudlowski, C., Bull, U. and Rath, W.: 1999, 'The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer.' *Int J Gynecol Cancer* **9**, 117-122.

Smith, G. T., Hubner, K. F., McDonald, T. and Thie, J. A.: 1998, 'Avoiding Second-Look Surgery and Reducing Costs in Managing Patients with Ovarian Cancer by Applying F-18-FDG PET.' *Clin Positron Imaging* **1**, 263.

Smith, G. T., Hubner, K. F., McDonald, T. and Thie, J. A.: 1999, 'Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer.' *Clin Positron Imaging* **2**, 63-70.

Soper, J. T.: 2001, 'Radiographic imaging in gynecologic oncology.' *Clin Obstet Gynecol* **44**, 485-94.

Talbot, J. N., Grahek, D., Kerrou, K., Younsi, N., de Beco, V., Colombet-Lamau, C., Petegnief, Y., Cailleux, N. and Montravers, F.: 2001, '[(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].' *Gynecol Obstet Fertil* **29**, 775-98.

Torizuka, T., Clavo, A. C. and Wahl, R. L.: 1997, 'Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine.' *J Nucl Med* **38**, 382-6.

Torizuka, T., Kanno, T., Futatsubashi, M., Okada, H., Yoshikawa, E., Nakamura, F., Takekuma, M., Maeda, M. and Ouchi, Y.: 2003, 'Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.' *J Nucl Med* **44**, 1051-6.

Torizuka, T., Nobezawa, S., Kanno, T., Futatsubashi, M., Yoshikawa, E., Okada, H., Takekuma, M., Maeda, M. and Ouchi, Y.: 2002, 'Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.' *Eur J Nucl Med Mol Imaging* **29**, 797-803.

Trampal, C., Maldonado, A., Sancho Cuesta, F., Morales, S., Senor de Uria, C., Panades, G. and Ortega, F.: 2000, '[Role of the positron emission tomography (PET) in suspected tumor recurrence when there is increased serum tumor markers].' *Rev Esp Med Nucl* **19**, 279-87.

Turlakow, A., Yeung, H. W., Salmon, A. S., Macapinlac, H. A. and Larson, S. M.: 2003, 'Peritoneal carcinomatosis: role of (18)F-FDG PET.' *J Nucl Med* **44**, 1407-12.

Vesselle, H. J. and Miraldi, F. D.: 1998, 'FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls.' *Radiographics* **18**, 805-23; discussion 823-4.

Wahl, R. L., Kaminski, M. S., Ethier, S. P. and Hutchins, G. D.: 1990, 'The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes.' *J Nucl Med* **31**, 1831-5.

Yen, R. F., Sun, S. S., Shen, Y. Y., Changlai, S. P. and Kao, A.: 2001, 'Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.' *Anticancer Res* **21**, 3691-4.

Yoshida, Y., Kurokawa, T., Kawahara, K., Tsuchida, T., Okazawa, H., Fujibayashi, Y., Yonekura, Y. and Kotsuji, F.: 2004, 'Incremental benefits of FDG

positron emission tomography over CT alone for the preoperative staging of ovarian cancer.' *AJR Am J Roentgenol* **182**, 227-33.

Yuan, C. C., Liu, R. S., Wang, P. H., Ng, H. T. and Yeh, S. H.: 1999, 'Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.' *J Reprod Med* **44**, 775-8.

Zhuang, H., Pourdehnad, M., Lambright, E. S., Yamamoto, A. J., Lanuti, M., Li, P., Mozley, P. D., Rossman, M. D., Albelda, S. M. and Alavi, A.: 2001, 'Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.' *J Nucl Med* **42**, 1412-7.

Zimny, M., Schroder, W., Wolters, S., Cremerius, U., Rath, W. and Bull, U.: 1997, '[18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results].' *Nuklearmedizin* **36**, 228-33.

Zimny, M., Siggelkow, W., Schroder, W., Nowak, B., Biemann, S., Rath, W. and Buell, U.: 2001, '2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.' *Gynecol Oncol* **83**, 310-5.